Cited by 136Down syndrome and intellectual disability researchDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation

Open access

Lott, Ira T., Doran, Eric, Nguyen, Vinh Q., Tournay, Anne, Head, Elizabeth, Gillen, Daniel L.·2011·American Journal of Medical Genetics Part A

DOI 10.1002/ajmg.a.34114PMC PMC3410645

Open this paper in CoChat — free account Open PDF

Abstract

Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non‐Down syndrome) population. This 2‐year randomized, double‐blind, placebo‐controlled trial assessed whether daily oral antioxidant supplementation (900 IU of alpha‐tocopherol, 200 mg of ascorbic acid and 600 mg of alpha‐lipoic acid) was effective, safe and tolerable for 53 individuals with Down syndrome and dementia. The outcome measures comprised a battery of neuropsychological assessments administered at baseline and every 6 months. Compared to the placebo group, those individuals receiving the antioxidant supplement showed neither an improvement in cognitive functioning nor a stabilization of cognitive decline. Mean plasma levels of alpha‐tocopherol increased ∼2‐fold in the treatment group and were consistently higher than the placebo group over the treatment period. Pill counts indicated good compliance with the regimen. No serious adverse events attributed to the treatment were noted. We conclude that antioxidant supplementation is safe, though ineffective as a treatment for dementia in individuals with Down syndrome and Alzheimer type dementia. Our findings are similar to studies of antioxidant supplementation in Alzheimer disease in the general population. The feasibility of carrying out a clinical trial for dementia in Down syndrome is demonstrated. © 2011 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/ajmg.a.34114

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Untitled work
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV
Roy, H. L. L., LeCam, L. M., & Neyman, J. (1969) · Revue de l Institut International de Statistique / Review of the International Statistical Institute · doi:10.2307/1402306 · Cited by 2,878
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Oxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 789
Assessment of Activities of Daily Living in Dementia: Development of the Bristol Activities of Daily Living Scale
Bucks, R. S., Ashworth, D. L., Wilcock, G. K., & Siegfried, K. (1996) · Age and Ageing · doi:10.1093/ageing/25.2.113 · Cited by 581
Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant
Bowry, V. W., Ingold, K. U., & Stocker, R. (1992) · Biochemical Journal · doi:10.1042/bj2880341 · Cited by 511
Action of ascorbic acid as a scavenger of active and stable oxygen radicals
Niki, E. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.6.1119s · Cited by 489

Show all 85 references

Sorted by citations

The role of antioxidants in the chemistry of oxidative stress: A review
Pisoschi, A. M., & Pop, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.040 · Cited by 2,963
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D. J., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 424
Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases
Gomes, M. B., & Negrato, C. A. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-80 · Cited by 275
Dementia in Down's syndrome
Ballard, C. G., Mobley, W. C., Hardy, J., Williams, G. H., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 289
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 262
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160836 · Cited by 244
Self-citation
Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of Down syndrome, autism, Fragile X and Rett syndrome
Valenti, D., Lidia de, B. A. R. I., Filippis, B. D., Henrion‐Caude, A., & Vacca, R. A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.012 · Cited by 203
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia
Marzia Perluigi, A., & Butterfield, D. A. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/724904 · Cited by 190
Mouse models of Down syndrome: gene content and consequences
Gupta, M., Dhanasekaran, A. R., & Gardiner, K. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9661-8 · Cited by 178
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Outcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
Self-citation
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Isaac, M. G. E. K. N., Clark, A. R., Rusted, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub3 · Cited by 125
Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer’s disease brain: A meta-analysis in human pathological specimens
Zabel, M., Nackenoff, A., Kirsch, W. M., Harrison, F. E., Perry, G., & Schrag, M. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.016 · Cited by 115
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
Gardiner, K. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s51476 · Cited by 119
The effect of N-acetylcysteine (NAC) on human cognition – A systematic review
Skvarc, D., Dean, O. M., Byrne, L. K., Gray, L. J., Lane, S. E., Lewis, M., Fernandes, B. S., Berk, M., & Marriott, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.013 · Cited by 111
Mitochondria-Targeted Antioxidants as Promising Drugs for Treatment of Age-Related Brain Diseases
Skulachev, V. P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111391 · Cited by 109
Neurologic complications of Down syndrome: a systematic review
Santoro, J. D., Pagarkar, D., Chu, D. T., Rosso, M., Paulsen, K. C., Levitt, P. R., & Rafii, M. S. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10179-w · Cited by 119
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub4 · Cited by 104
Metabolic Routes in Inflammation: The Citrate Pathway and its Potential as Therapeutic Target
Infantino, V., Pierri, C. L., & Iacobazzi, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180510124558 · Cited by 96
Down Syndrome and Dementia: Seizures and Cognitive Decline
Lott, I. T., Doran, E. W., Nguyen, V. Q., Tournay, A. E., Movsesyan, N., & Gillen, D. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111613 · Cited by 95
Self-citation
Aging and Down Syndrome
Head, E., Silverman, W. P., Patterson, D. W., & Lott, I. T. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/412536 · Cited by 100
Self-citation
Memory profiles in Down syndrome across development: a review of memory abilities through the lifespan
Godfrey, M., & Lee, N. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9220-y · Cited by 91
Frontal white matter integrity in adults with Down syndrome with and without dementia
Powell, D. K., Caban‐Holt, A., Jicha, G. A., Robertson, W. C., Davis, R., Gold, B. T., Schmitt, F. A., & Head, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.137 · Cited by 90
Self-citation
Antioxidants in Down syndrome
Lott, I. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.010 · Cited by 86
Self-citation
Accelerated bio‐cognitive aging in Down syndrome: State of the art and possible deceleration strategies
Franceschi, C., Garagnani, P., Gensous, N., Bacalini, M. G., Conte, M., & Salvioli, S. (2019) · Aging Cell · doi:10.1111/acel.12903 · Cited by 82
Antioxidant and Anti-Inflammatory Compounds from Edible Plants with Anti-Cancer Activity and Their Potential Use as Drugs
Cuevas-Cianca, S. I., Romero-Castillo, C., Gálvez-Romero, J. L., Juárez, Z. N., & Hernández, L. R. (2023) · Molecules · doi:10.3390/molecules28031488 · Cited by 88
Prospects for Improving Brain Function in Individuals with Down Syndrome
Costa, A. C. S., & Scott-McKean, J. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0089-3 · Cited by 83
Older adults with intellectual disability
Sinai, A., Bohnen, I., & Strydom, A. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328355ab26 · Cited by 78
Oxidative Stress and Mitochondrial Dysfunction in Down’s Syndrome: Relevance to Aging and Dementia
Coskun, P. E., & Busciglio, J. A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/383170 · Cited by 73
Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia
Sabbagh, M. N., Chen, K., Rogers, J., Fleisher, A., Liebsack, C., Bandy, D., Belden, C. M., Protas, H. D., Thiyyagura, P., Liu, X., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.01.006 · Cited by 72
The Role of Oxidative Stress in the Pathomechanism of Congenital Malformations
Laforgia, N., Mauro, A. D., Guarnieri, G. F., Varvara, D., Cosmo, L. D., Panza, R., Capozza, M., Baldassarre, M. E., & Resta, N. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7404082 · Cited by 70
A systematic review of the methodological and practical challenges of undertaking randomised-controlled trials with cognitive disability populations
Mulhall, P., Taggart, L., COATES, V. E., McAloon, T., & Hassiotis, A. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2018.01.032 · Cited by 66
Prenatal treatment of Down syndrome
Guedj, F., Bianchi, D. W., & Delabar, J. M. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000056 · Cited by 62
Systemic oxidative stress in children and teenagers with Down syndrome
Garlet, T. R., Parisotto, E. B., de Medeiros, G. D. S., Pereira, L. C. R., Moreira, E. A. D. M., Dalmarco, E. M., Dalmarco, J. B., & Filho, D. W. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.08.017 · Cited by 62
Vitamin E in aging persons with Down syndrome
Sano, M. C., Aisen, P. S. S., Andrews, H., Tsai, W., Lai, F., Dalton, A. J., McCallion, P., Zendell, A. L., Mintz, M., Young, J. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002714 · Cited by 63
Oxidative Stress and Down Syndrome. Do Antioxidants Play a Role in Therapy?
Muchová, J., Žitňanová, I., & Ďuračková, Z. (2014) · Physiological Research · doi:10.33549/physiolres.932722 · Cited by 63
Interventions for adults with mild intellectual disabilities and mental ill‐health: a systematic review
Osugo, M., & Cooper, S. (2016) · Journal of Intellectual Disability Research · doi:10.1111/jir.12285 · Cited by 55
Pharmacological interventions to improve cognition and adaptive functioning in down syndrome: strides to date.
Hart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
Pathways to cognitive deficits in Down syndrome
Sturgeon, X., Le, T., Ahmed, M. M., & Gardiner, K. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00005-4 · Cited by 52
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Down syndrome as a model of DNA polymerase beta haploinsufficiency and accelerated aging
Patterson, D. W., & Cabelof, D. C. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.10.001 · Cited by 48
Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study
Zis, P., Dickinson, M. J., Shende, S., Walker, Z., & Strydom, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120073 · Cited by 46
The contribution of the citrate pathway to oxidative stress in Down syndrome
Convertini, P., Menga, A., Andria, G., Scala, I., Santarsiero, A., Morelli, M. A. C., Iacobazzi, V., & Infantino, V. (2016) · Immunology · doi:10.1111/imm.12659 · Cited by 46
Pharmacological interventions for cognitive decline in people with Down syndrome
Livingstone, N., Hanratty, J., McShane, R. H., & Macdonald, G. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011546.pub2 · Cited by 44
Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms
Anderson-Mooney, A. J., Schmitt, F. A., Head, E., Lott, I. T., & Heilman, K. M. (2016) · Brain and Cognition · doi:10.1016/j.bandc.2016.02.007 · Cited by 44
Self-citation
Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain
Ahmed, M. M., Dhanasekaran, A. R., Tong, S., Wiseman, F. K., Fisher, E., Tybulewicz, V. L. J., & Gardiner, K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt017 · Cited by 43
Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review
de Sousa, C. N. S., Leite, C. M. G. D. S., Medeiros, I. D. S., Vasconcelos, L. C., Cabral, L. M., Patrocínio, C. F. V., Patrocínio, M. L. V., Mouaffak, F., Kébir, O., Macêdo, D. S., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0344-x · Cited by 42
The Impact of Oxidative Stress on Pediatrics Syndromes
Micangeli, G., Menghi, M., Profeta, G., Tarani, F., Mariani, A., Petrella, C., Barbato, C., Ferraguti, G., Ceccanti, M., Tarani, L., et al. (2022) · Antioxidants · doi:10.3390/antiox11101983 · Cited by 46
Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome
Pecze, L., Randi, E. B., & Szabó, C. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00225-8 · Cited by 43
Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Kovacic, P., & Somanathan, R. (2012) · Current Neuropharmacology · doi:10.2174/157015912804499429 · Cited by 41
Ageing of people with Down’s syndrome
Covelli, V., Raggi, A., Meucci, P., Paganelli, C., & Leonardi, M. (2015) · International Journal of Rehabilitation Research · doi:10.1097/mrr.0000000000000147 · Cited by 40
Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Kovacic, P., & Somanathan, R. (2012) · Current Neuropharmacology · doi:10.2174/157015912804143487 · Cited by 38
Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 36
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
Influence of dietary alpha-lipoic acid and lipid level on the growth performance, food intake and gene expression of peripheral appetite regulating factors in juvenile grass carp (Ctenopharyngodon idellus)
Huang, C.-C., Sun, J. H., Ji, H., Oku, H., Chang, Z.-G., Tian, J., Yu, E., & Xie, J. (2019) · Aquaculture · doi:10.1016/j.aquaculture.2019.02.054 · Cited by 35
Blood biomarkers of methylation in Down syndrome and metabolic simulations using a mathematical model
Obeid, R., Hartmuth, K., Herrmann, W., Gortner, L., Rohrer, T. R., Geisel, J., Reed, M. C., & Nijhout, H. F. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200162 · Cited by 35
Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome
Parisotto, E. B., Garlet, T. R., Cavalli, V. L. D. L. O., Zamoner, A., da Rosa, J. S., Bastos, J., Micke, G. A., Fröde, T. S., Pedrosa, R. C., & Wilhelm Filho, D. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.03.013 · Cited by 34
Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status
Walsh, D. M. A., Doran, E. W., Silverman, W. P., Tournay, A. E., Movsesyan, N., & Lott, I. T. (2015) · Journal of Intellectual Disability Research · doi:10.1111/jir.12200 · Cited by 32
Self-citation
Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome
Rueda, N., Flórez, J., Dierssen, M., & Martínez‐Cué, C. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.001 · Cited by 30
Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn
Kida, E., Rabe, A., Walus, M., Albertini, G., & Golabek, A. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.11.022 · Cited by 31
α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial
Nachvak, S. M., Neyestani, T. R., Mahboob, S., Sabour, S., Keshavarz, S.-A., & Speakman, J. R. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.97 · Cited by 29
Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials
Pagano, G., Talamanca, A. A., Castello, G., Cordero, M. D., d’Ischia, M., Gadaleta, M. N., Pallardó, F. V., Petrović, S. Ž., Tiano, L., & Zatterale, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120169 · Cited by 26
Apoptosis in Down’s syndrome: lessons from studies of human and mouse models
Rueda, N., Flórez, J., & Martínez‐Cué, C. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0785-3 · Cited by 31
Plasma and Tissue Concentrations of α-Tocopherol and δ-Tocopherol Following High Dose Dietary Supplementation in Mice
Baxter, L. L., Marugán, J., Xiao, J., Incao, A. A., McKew, J. C., Zheng, W., & Pavan, W. J. (2012) · Nutrients · doi:10.3390/nu4060467 · Cited by 25
Chemopreventive Effects of Alpha Lipoic Acid on Obesity-Related Cancers
Moon, H.-S. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000443994 · Cited by 25
Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome
Day, S. M., Yang, W., Wang, X., Stern, J. E., Zhou, X., Macauley, S. L., & Ma, T. (2019) · eNeuro · doi:10.1523/eneuro.0031-19.2019 · Cited by 21
Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities
Wallace, E. R., Harp, J. P., Pelt, K. L. V., Koehl, L., Caban‐Holt, A., Anderson-Mooney, A. J., Jicha, G. A., Lightner, D. D., Robertson, W. C., Head, E., et al. (2021) · Journal of Intellectual Disability Research · doi:10.1111/jir.12901 · Cited by 17
Self-citation
Copper accumulation in the brain causes the elevation of oxidative stress and less anxious behavior in Ts1Cje mice, a model of Down syndrome
Ishihara, K., Kawashita, E., Shimizu, R., Nagasawa, K., Yasui, H., Sago, H., Yamakawa, K., & Akiba, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.015 · Cited by 17
The Role of Oxidative Stress in Trisomy 21 Phenotype
Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Zbucka-Krętowska, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01417-6 · Cited by 21
Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells
Rachubinski, A. L., Maclean, K. N., Evans, J. R., & Bjugstad, K. B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.06.013 · Cited by 16
Cognitive Rehabilitation of Dementia in Adults with Down Syndrome: A Review of Non-Pharmacological Interventions
Fonseca, L. M., Navatta, A. C. R., Bottino, C. M. C., & Miotto, E. C. (2015) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000438858 · Cited by 16
Bi-stream CNN Down Syndrome screening model based on genotyping array
Feng, B. J., Hoskins, W., Zhang, Y., Meng, Z., Samuels, D. C., Wang, J., Xia, R., Liu, C., Tang, J., & Guo, Y. P. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0416-0 · Cited by 16
Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders
Bartesaghi, R., Vicari, S., & Mobley, W. C. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041521-103641 · Cited by 18
Can Individuals with Down Syndrome Benefit from Hippotherapy? An Exploratory Study on Gait and Balance
Portaro, S., Cacciola, A., Naro, A., Cavallaro, F., Gemelli, G., Aliberti, B., Luca, R. D., Calabrò, R. S., & Milardi, D. (2019) · Developmental Neurorehabilitation · doi:10.1080/17518423.2019.1646830 · Cited by 15
Triplication of HSA21 on alterations in structure and function of mitochondria
Ganguly, B. B., & Kadam, N. N. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.05.007 · Cited by 16
Computerized physical and cognitive training improves the functional architecture of the brain in adults with Down syndrome: A network science EEG study
Anagnostopoulou, A., Styliadis, C., Kartsidis, P. E., Romanopoulou, E. D., Zilidou, V. I., Karali, C., Karagianni, M. A., Klados, M. A., Paraskevopoulos, E., & Bamidis, P. D. (2021) · Network Neuroscience · doi:10.1162/netn_a_00177 · Cited by 15
Validation of the CAMCOG‐DS‐II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study
Ivain, P., Baksh, R. A., Saini, F., Idris, M., Tamayo‐Elizalde, M., Wells, J., Benejam, B., Loosli, S. V., Sandkühler, K., Wlasich, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70071 · Cited by 12
Alpha-lipoic Acid as a Pleiotropic Compound with Potential Therapeutic use in Diabetes and other Chronic Diseases
Gomes, M. B., & Negrato, C. A. (2015) · Medicine of Ukraine · doi:10.37987/1997-9894.2015.2(188).222520 · Cited by 12
Therapeutic applications of alpha-lipoic acid: A review of clinical and preclinical evidence (1998–2024)
Carnib, B. L., de Souza, E. A., Floresta, L. R. S., Lage, T. M., Pedro, I. D. R., Muniz, F. C., Silva, A. C. A., & de Oliveira, J. M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118480 · Cited by 13
The GABA A α5-selective Modulator, RO4938581, Rescues Protein Anomalies in the Ts65Dn Mouse Model of Down Syndrome
Block, A., Ahmed, M. M., Rueda, N., Hernandez, M., Martínez‐Cué, C., & Gardiner, K. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.12.038 · Cited by 13
Challenges faced in managing dementia in Alzheimer’s disease in patients with Down syndrome
Prasher, V. P., Mahmood, H., & Mitra, M. (2016) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s91754 · Cited by 9
Explores the role of fast fashion in sustainability: stylish killer for the environment
Guru, R., Grewal, D., & Thennarasu, P. (2022) · Journal of Textile Engineering & Fashion Technology · doi:10.15406/jteft.2022.08.00302 · Cited by 9
Effect of the one-carbon unit cycle on overall DNA methylation in children with Down's syndrome
Song, C., He, J., Chen, J., Liu, Y., Xiong, F., Wang, Y., & Li, T. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4439 · Cited by 9
Brain amyloid and the transition to dementia in Down syndrome
Keator, D. B., Doran, E. W., Taylor, L., Phelan, M. J., Hom, C. L., Tseung, K., van Erp, T. G. M., Potkin, S. G., Brickman, A. M., Rosas, H. D., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12126 · Cited by 9
Self-citation
Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies
de Oliveira, L. C., & Faria, D. D. P. (2022) · Molecules · doi:10.3390/molecules27103244 · Cited by 10
Outreach and engagement efforts in research on Down syndrome: An NIH INCLUDE Working Group consensus statement
Fidler, D. J., Riggs, N. R., Esbensen, A. J., Jackson‐Cook, C. K., Rosser, T. C., & Cohen, A. D. (2022) · International review of research in developmental disabilities · doi:10.1016/bs.irrdd.2022.09.006 · Cited by 8
Protective Effect of Alpha Lipoic Acid against Phenytoin Induced Behavioral Abnormalities in Rats
E, S. G. M. (2015) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000241 · Cited by 8
Improving Alzheimer's disease outcomes in Down's syndrome
Livingston, G., & Strydom, A. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61929-6 · Cited by 7
Advances in Research on Down Syndrome
Dey, S. (2018) · InTech eBooks · doi:10.5772/intechopen.68260 · Cited by 7
DOWN SENDROMLU BİREYLERDE BESLENME DURUMU
Yoldaş, K., & Yılmazer, Y. (2021) · European Journal of Science and Technology · doi:10.31590/ejosat.831542 · Cited by 7
Psychopharmacological treatments in Down syndrome and autism spectrum disorder: State of the research and practical considerations
Baumer, N., & Capone, G. T. (2023) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32069 · Cited by 6
The Role of Vitamin E in Aging and Alzheimer’s Disease
Eckert, G. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-05315-4_24 · Cited by 6
Cognitive and Behavioral Domains That Reliably Differentiate Normal Aging and Dementia in Down Syndrome
Harp, J. P., Koehl, L., Pelt, K. L. V., Hom, C. L., Doran, E. W., Head, E., Lott, I. T., & Schmitt, F. A. (2021) · Brain Sciences · doi:10.3390/brainsci11091128 · Cited by 6
Self-citation
Tiny Toes to Tau Tangles: Down's Syndrome and Its Association With Alzheimer's Disease
Puttagunta, S. M., Islam, R., Kundu, S., Jha, S. B., Rivera, A. P., Monar, G. V. F., Islam, H., & Sange, I. (2022) · Cureus · doi:10.7759/cureus.22125 · Cited by 6
Antioxidant Plant Polyphenols and Cognitive Disorders
Nowak, D. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_26 · Cited by 5
Long-term voluntary running modifies the levels of proteins of the excitatory/inhibitory system and reduces reactive astrogliosis in the brain of Ts65Dn mouse model for Down syndrome
Kida, E., Walus, M., Albertini, G., & Golabek, A. A. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147535 · Cited by 4
Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials
Hasina, Z., & Wang, C. C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.910424 · Cited by 4

Authors: Lott, I. T., Doran, E., Nguyen, V. Q., Tournay, A., Head, E., & Gillen, D. L.
Affiliations: University of California, Irvine (US)
University of Kentucky (US)
Corresponding author: Lott, Ira T.
ORCID: Lott, Ira T.
Nguyen, Vinh Q.
Head, Elizabeth
Gillen, Daniel L.
Venue: American Journal of Medical Genetics Part A
Publisher: Wiley
Published: 2011-07-07
Volume: 155
Issue: 8
Pages: 1939-1948
ISSN: 1552-4825 (ISSN-L)
1552-4833
DOI: 10.1002/ajmg.a.34114
PMC: PMC3410645
OpenAlex: W2027752708
Cited by: 136
References: 85
Citations by year: 2026: 2 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 14 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 15 · 2013: 5 · 2012: 22
FWCI: 14.15
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: American Journal of Medical Genetics Part A (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: University of California, Irvine
National Institute on Aging (AG 21912, AG 16573, P50AG016573, R01AG021912, P50-AG-21912)
National Center for Research Resources (UL1RR031985)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065160)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: Down syndrome, dementia, Alzheimer-type dementia, antioxidant supplementation, alpha-tocopherol, vitamin C, alpha-lipoic acid, oxidative stress, cognitive decline, plasma vitamin E, treatment efficacy, trial feasibility
MeSH terms: Alzheimer Disease, Antioxidants, Ascorbic Acid, Down Syndrome, Drug Combinations, Feasibility Studies, Female, Humans, Thioctic Acid, Male, Middle Aged, Pilot Projects, Treatment Outcome, alpha-Tocopherol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks